Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge.

The study found that extended post-discharge thromboprophylaxis with rivaroxaban for 35 days when compared with no anticoagulation, resulted in better clinical outcomes, including a reduction in major and fatal thromboembolic events without increasing major bleeding.

(thromboprophylaxis - any preventive measure that reduces the likelihood of the formation of blood clots)

To view the complete research article "Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19" click HERE.